Phase 1 N=48 Whole Blood Platelet Aggregation in Chronic Kidney Disease Patients on Aspirin Study
Chronic Kidney Disease
Primary: Whole Blood Platelet Aggregation to 0.5 Millimoles Arachidonic Acid — 21.0; 18.0; 0; 0 ohms
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=330 A Study to Learn How Well Nifurtimox Works and How Safe it is in Children Aged 0 to 17 Years With Chagas' Disease, an Inflammatory, Infectious Disease Caused by the Parasite Trypanosoma Cruzi
Chagas Disease
Primary: Part 1 - Percentage of Sero-reduction or Sero-conversion (Cured Subjects) — 32.9; 18.9 Percentage of subjects
Phase 3 N=6 High Dose Cyclophosphamide for Treatment of Scleroderma
Scleroderma
Primary: Improvement in the Modified Rodnan Skin Score. — 46.75 percent improvement from baseline
Phase 3 N=6 Study of Velaglucerase Alfa Enzyme Replacement Therapy in Japanese Patients With Gaucher Disease
Gaucher Disease
Primary: Number of Severe Adverse Events (SAE) — 1 events
N/A N=353 Rheumatoid Arthritis: Comparison of Active Therapies in Patients With Active Disease Despite Methotrexate Therapy
Rheumatoid Arthritis
Primary: Mean 48-week Change in DAS28 — -2.12; -2.29 units on a scale
Phase 2 N=90 Image Parkinson's Disease Progression Study
Parkinson's Disease
Primary: Change in Free-water Accumulation in the Substantia Nigra — 0.0009; 0.0041 arbitrary units (A.U.s)
N/A N=71 Xenodiagnosis After Antibiotic Treatment for Lyme Disease
Lyme Disease
Primary: Detection of Borrelia Burgdorferi in Ticks After Xenodiagnosis Procedure — 1; 0; 418; 319 Ticks
Phase 2 N=60 Copper Histidine Therapy for Menkes Diseases
Kinky Hair Syndrome
Primary: Gross Motor Development at 36 Mos of Age or at Death (Mos) — 13.743; 2.455; 15.667 Other - months
Phase 3 N=48 EMERALD: Effects of Metformin on Cardiovascular Function in Adolescents With Type 1 Diabetes
Type 1 Diabetes
Primary: Change in Insulin Sensitivity — 12.2; -2.4 (mg/kg/min)/(insulin) — p=0.005
Phase 2 N=140 Repurposing Anti-TNF for Treating Dupuytren's Disease
Dupuytren's Disease
Primary: Early Disease: Nodule Hardness at 12 Months — 58.1; 61.2 Durometer Arbitrary Units (AU)
Phase 2 N=20 A Phase 2 Study of the MET Kinase Inhibitor INC280 in Papillary Renal Cell Cancer
Kidney Cancer
Primary: Percentage of Participants With Response — 0; 15; 65; 10 percentage of participants
Phase 2 N=12 Pilot Study to Evaluate the Efficacy of Ruxolitinib in Alopecia Areata
Alopecia Areata
Primary: Change in SALT Score — 65.8; 24.8; 7.3 score on a scale
Phase 4 N=10 Short-term B-cell Depletion in Relapsing Multiple Sclerosis
Multiple Sclerosis
Primary: Number of Patients With a Return of Disease Activity After the Third Month Post-first-infusion — 3; 6 Participants
N/A N=130 Effectiveness of Implementing Shared Decision-Making on Quality of Care Among Patients With Lumbar Degenerative Diseases.
Lumbar Degenerative Disease · Shared Decision Making · Patient Decision Aids
Primary: The Change of Patients' Control Preference — 1; 1; 16; 14 Participants
Phase 2 N=6 Anakinra for Behcet s Disease
Autoimmune Connective Tissue Disorder · Immune System Diseases
Primary: Clinical Remission From Months 3-6 — 2 Participants